Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have earned an average rating of “Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Thirteen research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $123.38.
Several analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 price objective on shares of Axsome Therapeutics in a report on Friday, July 26th. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research report on Thursday. UBS Group cut their price objective on shares of Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Bank of America raised shares of Axsome Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $95.00 to $106.00 in a research note on Tuesday, August 6th. Finally, Mizuho reaffirmed a “buy” rating and set a $106.00 target price on shares of Axsome Therapeutics in a research report on Wednesday, June 12th.
Check Out Our Latest Stock Analysis on AXSM
Insider Activity at Axsome Therapeutics
Hedge Funds Weigh In On Axsome Therapeutics
A number of institutional investors have recently bought and sold shares of AXSM. Avidity Partners Management LP boosted its holdings in shares of Axsome Therapeutics by 54.8% in the 4th quarter. Avidity Partners Management LP now owns 459,400 shares of the company’s stock valued at $36,564,000 after acquiring an additional 162,600 shares during the last quarter. Jump Financial LLC purchased a new stake in Axsome Therapeutics in the fourth quarter valued at $669,000. Vanguard Group Inc. grew its position in Axsome Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock worth $298,474,000 after purchasing an additional 43,512 shares during the period. Bellevue Group AG raised its stake in shares of Axsome Therapeutics by 7.9% during the 1st quarter. Bellevue Group AG now owns 685,476 shares of the company’s stock valued at $54,701,000 after buying an additional 50,104 shares during the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at about $3,980,000. 81.49% of the stock is owned by hedge funds and other institutional investors.
Axsome Therapeutics Trading Up 1.0 %
Shares of NASDAQ AXSM opened at $87.99 on Friday. Axsome Therapeutics has a twelve month low of $55.02 and a twelve month high of $98.40. The firm has a market cap of $4.18 billion, a PE ratio of -13.79 and a beta of 1.26. The business has a fifty day simple moving average of $83.11 and a two-hundred day simple moving average of $78.96. The company has a quick ratio of 3.09, a current ratio of 3.20 and a debt-to-equity ratio of 1.25.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Featured Stories
- Five stocks we like better than Axsome Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- High Flyers: 3 Natural Gas Stocks for March 2022
- MarketBeat Week in Review – 8/19 – 8/23
- What is the NASDAQ Stock Exchange?
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.